The detection of preclinical Parkinson's disease: What is the role of positron emission tomography?
β Scribed by Dr. Guy V. Sawle
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- English
- Weight
- 715 KB
- Volume
- 8
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
On clinical criteria alone, the diagnosis of early Parkinson's disease can be difficult and, by definition, the prospective recognition of preclinical Parkinson's disease is impossible. Positron emission tomography (PET) using [^18^F]dopa as tracer has been proposed as a means of identifying patients with preclinical disease. The number of subjects detected to date has been few; most have been identified by serendipity or during the course of family studies. This review examines the significance of a single abnormal scan in an apparently healthty subject in terms of the relationship between normal and abnormal values and the time course of the disease.
π SIMILAR VOLUMES
We evaluated the role of positron emission tomography (PET) with ["F)deoxyglucose (FDG) (FDG-PET) for planning surgery in 53 patients who had temporal lobectomy for uncontrolled seizures at the National Institutes of Health from 1981 to 1990. Investigators blinded to PET data used results of telemet
## Abstract Striatal dopamine D~2~ receptor binding was studied in vivo with positron emission tomography in seven patients with early Parkinson's disease using [^11^C]βraclopride. The patients had unilateral symptoms and none of them had received levodopa treatment. The accumulation of [^11^C]βrac